

- Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 2005;352:1851–1860.
- Hampel H, Panescu J, Lockman J, et al. Comment on: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res* 2007;67:9603.
- Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clin Genet* 2009;75:141–149.
- Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology* 1996;110:1020–1027.
- Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet* 2005;42:491–496.
- Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304–2310.
- Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. *Gastroenterology* 2005;129:415–421.
- Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology* 2009;137:1621–1627.
- Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med* 2009;11:42–65.
- Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst* 2010;102:193–201.
- Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology* 2008;135:419–428.
- Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. *J Clin Oncol* 2012;30:958–964.
- Lynch HT, Lynch PM, Pester J, et al. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. *Arch Intern Med* 1981;141:607–611.
- South CD, Hampel H, Comeras I, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. *J Natl Cancer Inst* 2008;100:277–281.
- Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. *N Engl J Med* 1995;332:839–847.
- Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum* 1991;34:424–425.
- Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999;116:1453–1456.
- Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst* 1997;89:1758–1762.
- Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261–268.
- Morrison J, Bronner M, Leach BH, et al. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach. *Scand J Gastroenterol* 2012;46:1340–1348.
- de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. *J Clin Oncol* 2010;28:3380–3387.
- Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–5257.
- Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol* 2008;26:5783–5788.
- Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. *Gastroenterology* 2001;121:830–838.
- Niessen RC, Kleibeuker JH, Westers H, et al. PMS2 involvement in patients suspected of Lynch syndrome. *Genes Chromosomes Cancer* 2009;48:322–329.
- Zigelboim I, Powell MA, Babb SA, et al. Epitope-positive truncating MLH1 mutation and loss of PMS2: Implications for IHC-directed genetic testing for Lynch syndrome. *Fam Cancer* 2009;8:501–504.
- Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. *J Clin Oncol* 2002;20:1043–1048.
- Ruszkiewicz A, Bennett G, Moore J, et al. Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. *Pathology* 2002;34:541–547.
- Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary nonpolyposis colorectal cancer. *Fam Cancer* 2007;6:301–310.
- Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. *J Med Genet* 2009;46:793–802.
- Mutch DG, Powell MA, Mallon MA, et al. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. *Am J Obstet Gynecol* 2004;190:935–942.
- Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome—a review. *J Genet Couns* 2011;20:5–19.
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. *Genet Med* 2009;11:35–41.
- Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. *Genet Med* 2010;12:93–104.
- Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. *Ann Intern Med* 2011;155:69–79.
- Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. *Genes Chromosomes Cancer* 2009;48:737–744.
- Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol* 2009;27:4793–4797.
- National Comprehensive Cancer Network. NCCN Guidelines & Clinical Resources. NCCN Guidelines for Detection, Prevention, and Risk Reduction [v.1.2012]. 2012. http://www.nccn.org/professionals/physician_gls/recently_updated.asp
- Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 2011;378:2081–2087.